stockrow
Monday 9 November 2026
Export ABOS’s income statement to Excel — free account
Acumen Pharmaceuticals, Inc.
ABOS- EPS
- +20.3%
- Free cash flow
- +12.6%
- Total debt
- −14.3%
Quarter to September 2026, against a year earlier
0.22
0.01
+4.76%
Follow ABOS
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | — | — |
+8 more quarters Free account |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
1.74 | 2.35 | 4.39 | 3.89 | |
Current Ratio |
1.89 | 2.47 | 4.55 | 4.07 | |
Net Debt/EBITDA |
2.03 | 2.40 | 4.62 | 3.42 | |
Debt/Assets |
30.70% | 27.21% | 23.23% | 25.37% | |
Debt/Equity |
0.76 | 0.55 | 0.35 | 0.44 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.05 | 0.55 | 1.16 | 0.76 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
(25.84) | (29.76) | (19.78) | (23.18) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.37) | (0.25) | (0.38) | (0.32) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.37) | (0.25) | (0.38) | (0.32) | |
Cash per Share |
1.09 | 1.53 | 2.03 | 1.93 | |
Shareholders Equity per Share |
0.48 | 0.79 | 1.38 | 1.16 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.48 | 0.79 | 1.38 | 1.16 | |
Free Cash Flow |
(26.65) | (18.07) | (24.13) | (19.10) | |
Working Capital |
40.05 | 68.67 | 103.87 | 92.25 | |
Capital Expenditures |
— | — | — | 0.00 | |
Net Current Asset Value |
34.18 | 56.77 | 86.94 | 69.85 | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
— | — | — | 0.00 | |
| Other line items | |||||
Average Payables |
3.37 | 7.74 | 1.36 | 3.10 | |
Average Assets |
113.89 | 143.95 | 169.05 | 180.91 | |
Average Common Equity |
63.89 | 87.17 | 121.50 | 126.12 |
Columns are period end dates · fundamentals updated 2 Nov 2026